16 completed, 8 unknown, 7 recruiting, 6 active not recruiting. 38 Phase 2, 9 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Mucosal Melanoma: new trials by email Literature Review of Mucosal Melanoma trials Research Report on Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors KUP-101A - Cutaneous Melanoma, Mucosal Melanoma | Phase 1 | Recruiting | Kupando GmbH | 21 | 2026-07-03 | 2026-08-12 |
| Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery Sintilimab, Dacarbazine or Temozolomide, Cisplatin - Mucosal Melanoma, PD-L1 Positive | Phase 2 | Recruiting | The First Hospital of Jilin University | 220 | 2026-04-10 | 2026-09-03 |
| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Recruiting | Melanoma Institute Australia | 494 | 2026-02-09 | 2026-02-19 |
| Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma Iparomlimab and Tuvoraleimab injection+Bev+nab-PC - Acral Melanoma, Mucosal Melanoma | Phase 2 | Not yet recruiting | Fudan University | 48 | 2026-02-01 | 2026-01-16 |
| Neo-adjuvant Immunotherapy in Patients With Localized Melanoma Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution) - Cutaneous Melanoma, Stage III, Mucosal Melanoma | Phase 2 | Recruiting | UNICANCER | 50 | 2026-01-12 | 2026-07-21 |
| Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma Carilizumab and Apatinib - Mucosal Melanoma | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2025-11-30 | 2025-11-19 |
| A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202 - Melanoma Metastatic, Uveal Melanoma, Metastatic | Phase 1 | Terminated | Alpha-9 Oncology USA Inc. | 5 | 2025-11-19 | 2026-08-31 |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma AK104+Axitinib, AK112+Axitinib - Melanoma, Mucosal Melanoma | Phase 1 | Enrolling by invitation | Peking University Cancer Hospital & Institute | 60 | 2024-05-28 | 2026-07-13 |
| Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma Pembrolizumab, Lenvatinib - Mucosal Melanoma | Phase 2 | Withdrawn | Melanoma Institute Australia | 2024-03-01 | 2024-06-26 | |
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Pembrolizumab, Vactosertib - Acral Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Yonsei University | 14 | 2023-02-09 | 2025-04-02 |
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma TBio-4101, Cyclophosphamide, Fludarabine - Metastatic Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-11-22 | 2026-04-02 |
| Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Olaparib - Recurrent Metastatic Melanoma, Cutaneous Melanoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2022-10-04 | 2024-01-19 | |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Anal Melanoma, Bladder Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 101 | 2022-08-11 | 2026-08-04 |
| A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma YH003, Pembrolizumab, albumin paclitaxel - Mucosal Melanoma | Phase 2 | Completed | Eucure (Beijing) Biopharma Co., Ltd | 20 | 2022-06-13 | 2025-01-06 |
| Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib - Mucosal Melanoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2022-05-17 | 2026-02-18 |
| Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Mural Oncology, Inc | 173 | 2021-09-27 | 2025-06-10 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-13 |
| Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM endoscopic surgery, intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy, Chemotherapy drug - Mucosal Melanoma, Sinonasal Melanoma | Early Phase 1 | Unknown | Eye & ENT Hospital of Fudan University | 28 | 2021-08-10 | 2021-08-17 |
| The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma Telephone follow-up - FDG PET, Mucosal Melanoma | Completed | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 68 | 2021-01-01 | 2026-04-01 |
Showing 20 of 50. Sign in to see all of them.
Melanoma (27) · Uveal Melanoma (13) · Neoplasms (3) · Carcinoma, Basal Cell (2) · Esophageal Neoplasms (2) · Neoplasm Metastasis (2) · Skin Neoplasms (2) · Uterine Cervical Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Dysplastic Nevus Syndrome (1)
Neoplasms by Histologic Type (27) · Neoplasms by Site (27) · Neoplasms, Germ Cell and Embryonal (27) · Neoplasms, Nerve Tissue (27) · Neuroectodermal Tumors (27) · Neuroendocrine Tumors (27) · Nevi and Melanomas (27) · Skin Diseases (27) · Skin and Connective Tissue Diseases (27) · Skin Neoplasms (25) · Neoplasms (24) · Eye Diseases (13) · Eye Neoplasms (13) · Uveal Diseases (13) · Uveal Neoplasms (13)
pembrolizumab (10) · Nivolumab (9) · Ipilimumab (8) · CTLA-4 Antigen (4) · Axitinib (2) · Disulfides (2) · Immunoglobulin G (2) · Interleukin-2 (2) · Magnetic Resonance Spectroscopy (2) · Radiosurgery (2) · Specimen Handling (2) · Taxes (2) · Temozolomide (2) · apatinib (2) · lenvatinib (2)
National Cancer Institute (NCI) (9) · Peking University Cancer Hospital & Institute (4) · Dana-Farber Cancer Institute (2) · Fudan University (2) · M.D. Anderson Cancer Center (2) · Melanoma Institute Australia (2) · Academic and Community Cancer Research United (1) · Alpha-9 Oncology USA Inc. (1) · AnewPharma (1) · Ascentage Pharma Group Inc. (1) · CHU de Reims (1) · Craig L Slingluff, Jr (1) · Emory University (1) · Eucure (Beijing) Biopharma Co., Ltd (1) · Eye & ENT Hospital of Fudan University (1)
United States (25) · China (14) · Australia (8) · Canada (5) · South Korea (3) · Spain (3) · France (2) · Belgium (1) · Denmark (1) · Germany (1) · Ireland (1) · Italy (1) · Portugal (1) · Russia (1) · Switzerland (1)
Jun Guo, MD (2) · Alexander N Shoushtari (1) · Alexander Shoushtari (1) · Alexander Shoushtari, MD (1) · Amod Sarnaik, MD (1) · Arash Yavari, MBBS (1) · Ari M Vanderwalde (1) · Christopher D Lao (1) · Craig L Slingluff, Jr., M.D. (1) · Craig Slingluff (1) · David H Lawson (1) · Erez Baruch, MD,PHD (1) · F. Stephen Hodi, MD (1) · Georgina Long (1)
PMID 36648215, PMID 23248256, PMID 25609545, PMID 26351350, PMID 30588103, PMID 34413169, PMID 35121932, PMID 36856617, PMID 37104746, PMID 37592104, PMID 38577337, PMID 39342463, PMID 39633321, PMID 40638872, PMID 40811146, PMID 42093981
2025 (2), U01CA154967 (2), U10CA021115 (2), U10CA180821 (2), U10CA180888 (2), 2023 (1), P30CA015083 (1), P30CA015704 (1), P30CA076292 (1), P30CA138292 (1), U10CA032102 (1), U10CA180820 (1)